Cannabinoids for Taxane Induced Peripheral Neuropathy

Phase 2 Terminated 12 enrolled New York State Psychiatric Institute

RandomizedParallel-groupTriple-blindTreatment

Summary

Taxane-induced peripheral neuropathy (TIPN) affects a significant number of women undergoing breast cancer treatment. Some patients may need to shorten their course of treatment, and do not receive the full benefit of chemotherapy as a result. Rodent studies have shown that the cannabinoids may significantly improve hyperalgesia and allodynia induced by paclitaxel. The goal of this study is to investigate the cannabinoids THC and CBD for TIPN.

Timeline

Start: 2019-09-01
Primary completion: 2021-08-30
Completion: 2021-08-30

Outcome

Outcome not reported

Stopped (Business): “Funding being sought”

Publications

Haney M, Choo TH, Tiersten A, Levin FR, Grassetti A, DeSilva N, Arout CA, Martinez D. Oral Cannabis for Taxane-Induced Neuropathy: A Pilot Randomized Placebo-Controlled Study. Cannabis Cannabinoid Res. 2025 Oct;10(5):631-639. doi: 10.1089/can.2025.0028. Epub 2025 Jul 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	100 mg	Oral
Subject	Δ9-tetrahydrocannabinol	Unknown	5 mg	Oral